The One With The Fake Cancer Detection

The product sounds great: “The Gold Standard to monitor metastic breast cancer. Our Serum-2 test provides a more accurate representation of HER-2 status, facilitating more appropriate treatment strategies.” NanoMolecularDX is “executing a commercialization strategy” for this test and others.  In July is closed on $1 million of seed funding. I’m an advocate for cancer research and … Read more »

Compliance Bricks and Mortar – John McCain Edition

Here are some of the compliance-related stories that recently caught my attention. Standardizing IRR Calculations and Related Disclosures – The SEC Continues to Focus on Private Equity Practice by Vivek Pingili, Esq. In recent years the SEC has closely examined private equity fund performance and reporting during routine exams. The importance of this topic came … Read more »

CCO Liability: What Risks Remain and What You Can Do to Minimize Them

IA Watch produced an informative webinar on CCO Liability. These are my notes. Carl Ayers (Moderator)  Publisher, Regulatory Compliance Watch Brian Moran, Executive director and CCO Sterling Capital Management Joseph McGill, J.D., Chief Compliance Officer Lord, Abbett & Co. Kelley Howes, Counsel Morrison Foerster Heidi Vonderheide of Ulmer & Berne LLP First up was Heidi. Her … Read more »